News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

Montana BioScience Alliance
|
July 10, 2022

Since 2004, approximately 1,200 clinical trials have been conducted in Montana. That’s just one of the facts in the report “Research in Your Backyard: Developing Cures, Creating Jobs – Pharmaceutical Clinical Trials in Montana.” The report was the subject of a recent seminar in Billings sponsored by the Montana BioScience Alliance and the Pharmaceutical Research and Manufacturers of America (PhRMA).

Montana Tech was recently awarded a five-year, $24 million grant from the Army Research Laboratory to develop a program called “Materials Technology for Rare Earth Elements Processing.” This program, which responds to a critical national need to develop a supply chain for rare earth elements, is a multidisciplinary effort that will use Montana as a model for locating rare earth elements in primary and secondary sources.

Emory Hoelscher-Hull was recently awarded a prestigious public health grant based on her research into water quality in Montana; Pilar Santos was one of four winners of the 2022 Association of Environmental Health Academic Program student research competition, and Sarah Warnke was a runner-up in the competition. All three students were mentored with support from Montana NSF EPSCoR by Dr. Mari Eggers, an Assistant Research Professor in the Department of Microbiology and Immunology.

Montana’s Tonix Pharmaceuticals has announced the design of a new Phase 2 clinical trial of TNX-1300 for the treatment of cocaine intoxication. This new protocol has the potential to serve as a pivotal trial. TNX-1300 is a recombinant enzyme that efficiently degrades and metabolizes cocaine in cocaine users, as demonstrated in a prior Phase 2a randomized, double-blind, placebo-controlled clinical study, providing support of the use of TNX-1300 as a treatment for cocaine intoxication. The company plans to submit the new protocol to the […]

Montana BioScience Alliance and BIO
|
July 2, 2022

Covid-19 opened the world’s eyes to the wonders of biotechnology. Unfortunately, though, coverage of the industry isn’t always the best. To provide more information about the ways bioscience is curing disease, solving climate change, and feeding and fueling the world in more sustainable ways, the Montana BioScience Alliance is joining with BIO to develop easy-to-read and easy-to-share news articles by independent journalists, editors, and content creators, as well as smart analysis by BIO experts. You can find it now on Bio.News.

ARTICLES OF INTEREST

Researchers from Diaceutics and the Personalized Medicine Coalition has published a special report in JCO Precision Oncology  that provides an in-depth look at United States health systems’ efforts to deploy potentially paradigm-shifting targeted and immuno-oncology drugs to improve care for lung cancer patients.

Doctors have told health services to prepare for a new era of cancer screening after a study found a simple blood test could spot multiple cancer types in patients before they develop clear symptoms.

It’s been 60 years since President Kennedy delivered his iconic moonshot speech, marking a goal for America to launch a man into space to step foot on the moon, and bring him back to Earth. On Sept. 12, President Biden gave a speech at the Kennedy Presidential Library in Boston, outlining the progress on his own self-described moonshot: ending cancer.

The National Institute on Aging (NIA) offers early-stage funding opportunities to small businesses and researchers looking to commercialize innovative treatments or technologies to help people enjoy healthier lives as they age. The NIA Small Business Program is accepting applications for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. Learn more about these open opportunities. The next deadline to apply is September 6, 2022. 

The federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs offer a lifeline to small medical technology companies that otherwise would not be able to secure the initial funding necessary for expensive research and development.

NEWSLETTER

Newsletter
|
November 30, 2022

View the Fall 2022 now!

Newsletter
|
August 25, 2022